LOS ANGELES--(BUSINESS WIRE)--Oct. 4, 2005--Universal Detection Technology (OTCBB:UDTT)(FWB:PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, has announced an agreement with Rutgers University to commence independent testing of the Company's next-generation BSM-2000 monitor, an anthrax and bio-threat detection device based on advanced technology developed by scientists in the NASA space program.
The Rutgers Center for Advanced Infrastructure and Transportation (CAIT), established in 1998, is testing the UDTT technology as part of a national program of university transportation centers funded by the U.S. Department of Transportation (USDOT). The mission of the federally supported Rutgers CAIT program includes improvement of the nation's transportation infrastructure in the critical areas of safety and national security.
"Our discussions with authorities from Rutgers' CAIT to test UDTT's bacterial spore monitors is to obtain a reputable, independent third party validation of our bio-terror detection technology, which is capable of detecting an increase in spore count in the ambient air, enabling a powerful new way to monitor and warn for the presence of anthrax and other dangerous biological threats," said Jacques Tizabi, Chairman and CEO of UDTT.
UDTT is the exclusive licensor of proprietary technology originally developed by NASA's Jet Propulsion Laboratory (JPL) for the Mars exploration missions. UDTT's BSM-2000 is a next-generation detection and monitoring device that combines JPL's spore detection technology with UDTT's proprietary aerosol capture technology. The BSM-2000 device is designed to detect the presence of airborne infectious spores, such as anthrax and other dangerous biological agents.
Under the latest oral agreement with UDTT, Rutgers' CAIT researchers will conduct the new testing phase of UDTT's BSM-2000 monitor to evaluate its use as a powerful new anti-terrorism technology to further enhance the nation's homeland security readiness. The Rutgers' CAIT program, which also develops computer software systems to simulate evacuation procedures in public facilities, previously examined the feasibility of incorporating UDTT's BSM-2000 sensors in its emergency response procedures. The new agreement is designed to evaluate the function of the BSM-2000 to further the integration of the UDTT proprietary technology into its security proposals to the federal government. The Company believes that third-party validation from the federally supported program at Rutgers would provide additional credibility for UDTT's detection technology platform.
"We believe that the Rutgers' independent validation assessments will confirm the results of all our previous test phases of the BSM-2000 detector for anthrax and other potentially dangerous biological and bioterrorism threats," said Mr. Tizabi. "We expect the validation of our product by Rutgers' would significantly enhance our efforts for large-scale marketing and distribution activities to deliver BSM-2000 products for use in a very broad range of potential sites where the public is vulnerable to attacks from bioterrorism, including post office facilities, airports and other busy venues. UDTT's sales and marketing team has already started initial marketing programs with the BSM-2000 and is working with several early adopters interested in utilizing our technology platform to create safer environments for their staff, customers and the public at large."
UDTT has designed the BSM-2000 as an early-warning anthrax detection device that can alert to the presence of anthrax spores, in the period bioterrorism experts refer to as the "detect-to-treat" time frame. This is the period when early commencement of safety measures, such as evacuation and medical treatment, can provide the greatest level of protection and save the most lives. Anthrax has been named one of the gravest of biological dangers by such authorities as former CIA director George Tenet. One expert study estimated that a release of just two pounds of weapons grade anthrax could result in more than 100,000 deaths; homeland security authorities have said early warning of such biological attacks is one of the most important factors in protecting the public.
About Rutgers University's Center for Advanced Infrastructure and Transportation
The Center for Advanced Infrastructure and Transportation (CAIT), established in 1998, is a part of the national university transportation centers program funded by the U.S. Department of Transportation (USDOT). The mission of the Center is to help upkeep and maintain the nation's aging transportation infrastructure through research, education and workforce training. The theme of the Center is to be a catalyst for creating a multi-modal transportation infrastructure research and education paradigm that incorporates input from members of the Transportation Infrastructure Systems (TIS) community. The Center is active in TIS education, research, and technology transfer in the critical areas of safety, mobility, economic growth, human and natural environment, and national security. The unique feature of the Center is its focus on implementation of advanced and cutting-edge technologies, from broad and interdisciplinary sources, used for efficient maintenance and operation of multi-modal transportation infrastructure systems in high volume and heavily utilized intermodal corridors. The center utilizes the heavily used transportation corridors of New Jersey as a test-bed for implementation of advanced technologies in pavement management systems, intelligent transportation systems, congestion management, traffic safety, maritime freight movement, transportation infrastructure safety and security, and beneficial use of waste materials in transportation applications. The multidisciplinary approach of the center in addressing pressing operation problems has led to strong partnerships with stakeholders in the region including transportation agencies, the private sector and numerous other academic and research institutions.
About Universal Detection Technology
Universal Detection Technology (UDTT), founded in 1973, is a developer of advanced monitoring and early-warning technologies whose mission is to help meet today's heightened security and defense requirements in the global war on terror. The Company's intellectual property portfolio includes exclusive worldwide commercial licensing of technology developed by NASA's Jet Propulsion Laboratory (JPL) and its own proprietary aerosol capture technology, which are combined in the Company's initial monitoring device, the BSM-2000. Management believes that the Company's technology, together with third party technologies and devices, has positioned it to capitalize on growth and value opportunities related to Homeland Security. For more information, please visit http://udtt.invrel.net or http://www.udetection.com.To view investor-specific information about the Company, including recent news and other data, please visit http://www.trilogy-capital.com/tcp/udt. To read or download an Investor Fact Sheet about the Company, please visit http://www.trilogy-capital.com/tcp/udt/factsheet.html. Universal Detection Technologies is also listed on the Frankfurt Stock Exchange under the ticker symbol PO8.
Forward-Looking Statements
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the validation by Rutgers of our bio-terror detection technology following its testing of the BSM-2000, funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt, our ability to timely and cost effectively complete the development and testing of our products targeted to the bio-chemical market, our ability to commercially produce our products on a profitable basis, commercial acceptance of our products, product price volatility, product demand, market competition and general economic conditions, and other factors described in the Company's filings with the Securities and Exchange Commission. We undertake no obligation and do not intend to revise or update publicly any forward looking statements for any reason.
Contacts
Universal Detection Technology
Jacques Tizabi, 310-248-3655
jtizabi@udetection.com
or
Investor Relations
Trilogy Capital Partners
Paul Karon, 800-592-6067
paul@trilogy-capital.com
Leave a comment